Consort Medical (CSRT) Sets New 12-Month Low Following Analyst Downgrade

Consort Medical plc (LON:CSRT)’s share price hit a new 52-week low during trading on Wednesday after Shore Capital lowered their price target on the stock from GBX 1,255 to GBX 1,215. Shore Capital currently has a hold rating on the stock. Consort Medical traded as low as GBX 742 ($9.70) and last traded at GBX 745 ($9.73), with a volume of 32226 shares traded. The stock had previously closed at GBX 770 ($10.06).

Separately, Royal Bank of Canada upgraded Consort Medical to an “outperform” rating and reduced their price objective for the stock from GBX 1,430 ($18.69) to GBX 1,320 ($17.25) in a research report on Tuesday.

The firm also recently announced a dividend, which will be paid on Friday, February 15th. Shareholders of record on Thursday, January 17th will be paid a dividend of GBX 7.60 ($0.10) per share. The ex-dividend date of this dividend is Thursday, January 17th. This represents a yield of 0.99%.

ILLEGAL ACTIVITY WARNING: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at

Consort Medical Company Profile (LON:CSRT)

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.

Read More: Buyback

Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with's FREE daily email newsletter.

Leave a Reply